Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluation of a New Malaria Control Strategy Amongst Gold Miners Working Illegally in French Guiana (Malakit) (MALAKIT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03695770
Recruitment Status : Completed
First Posted : October 4, 2018
Last Update Posted : May 20, 2021
Sponsor:
Collaborators:
Dr Stephen Vreden (Foundation for Scientific Research Suriname : SWOS)
Dr Martha Suarez-Mutis (Substitute Chief of Fundação Oswaldo Cruz: Fiocruz)
Dr Maylis Douine (Centre Hospitalier de Cayenne)
Information provided by (Responsible Party):
Centre Hospitalier de Cayenne

Brief Summary:

Illegal gold miners in French Guiana, a French overseas territory ('département') located in Amazonia, often carry malaria parasites (up to 46.8%). While the Guiana Shield Region aims at malaria elimination, the high prevalence of Plasmodiumin this hard-to-reach population in conjunction with frequent incorrect use of artemisinin-based anti-malarials could favor the emergence of resistant parasites. Due to geographical and regulatory issues in French Guiana, usual malaria control strategies cannot be implemented in this particular context.Therefore, new strategies targeting this specific population in the forest are required.

Numerous discussions among health institutions and scientific partners from French Guiana, Brazil and Suriname have led to an innovative project based on the distribution of kits for self-diagnosis and self-treatment of Plasmodium infections. The kit-distribution will be implemented at "resting sites", which are areas across the border of French Guiana regularly frequented by gold miners. The main objective is to increase the appropriate use and complete malaria treatment after a positive malaria diagnosis with a rapid test, which will be evaluated with before-and-after cross-sectional studies. Monitoring indicators will be collected from health mediators at the time of kit distribution and during subsequent visits, and from illegal gold miners themselves, through a smartphone application. The project funding is multisource, including Ministries of Health of the three countries, WHO/PAHO, and the European Union.


Condition or disease Intervention/treatment Phase
Malaria Public Health Other: kit for self-diagnosis and self-treatment Not Applicable

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 3733 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: before/after study design
Masking: None (Open Label)
Primary Purpose: Other
Official Title: Evaluation of a New Malaria Control Strategy Amongst Gold Miners Working Illegally in French Guiana (Malakit)
Actual Study Start Date : April 16, 2018
Actual Primary Completion Date : March 30, 2020
Actual Study Completion Date : March 30, 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Malaria

Arm Intervention/treatment
Experimental: target population
All the target population should be included in the experimental arm
Other: kit for self-diagnosis and self-treatment
distribution of kits for malaria self-diagnosis and self-treatment after a training by health facilitators




Primary Outcome Measures :
  1. KAP Questionnaire [ Time Frame: 12 months ]
    change the part of illegal gold miners in French Guiana who take a correct antimalarial treatment (with artemisinin-combined therapy) with a good adherence and after a positive rapid diagnostic test.


Secondary Outcome Measures :
  1. malaria prevalence [ Time Frame: 12 months ]
    change PCR-Plasmodium prevalence amongst gold miners working illegally in French Guiana

  2. KAP questionnaire [ Time Frame: 12 months ]
    change the use of protection measures against mosquitoes



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   15 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • over 15 years-old
  • working or accompanying someone working in illegal gold mining in French Guiana
  • agreing to take part of the study
  • to have parents authorization if age between 15 and 17 ;
  • capable of performing a self-RDT during the training (validation by the facilitator);

Exclusion Criteria:

  • refusing to participate in the study ;
  • under 15 years old ;
  • no parents authorization ;
  • weighing less than 35 kg ;
  • who has not been able to perform a self-RDT during the training (invalidation by the facilitator).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03695770


Locations
Layout table for location information
Brazil
Fondation Oswaldo Cruz
Rio De Janeiro, Brazil
Suriname
Foundation for Scientific Research Suriname (SWOS)
Paramaribo, Suriname
Sponsors and Collaborators
Centre Hospitalier de Cayenne
Dr Stephen Vreden (Foundation for Scientific Research Suriname : SWOS)
Dr Martha Suarez-Mutis (Substitute Chief of Fundação Oswaldo Cruz: Fiocruz)
Dr Maylis Douine (Centre Hospitalier de Cayenne)
Publications:

Layout table for additonal information
Responsible Party: Centre Hospitalier de Cayenne
ClinicalTrials.gov Identifier: NCT03695770    
Other Study ID Numbers: MALAKIT
First Posted: October 4, 2018    Key Record Dates
Last Update Posted: May 20, 2021
Last Verified: May 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Malaria
Protozoan Infections
Parasitic Diseases
Infections
Vector Borne Diseases